Kasahara, Masato
Kuwabara, Yoshihiro
Moriyama, Toshiki
Tanabe, Kazuaki
Satoh-Asahara, Noriko
Katsuya, Tomohiro
Hiramitsu, Shinya
Shimada, Hidetaka
Sato, Tosiya
Saito, Yoshihiko
Nakagawa, Takahiko http://orcid.org/0000-0002-0127-1529
Funding for this research was provided by:
Fuji Yakuhin Co., Ltd (Not applicable)
Article History
Received: 24 July 2019
Accepted: 31 October 2019
First Online: 15 November 2019
Compliance with ethical standards
:
: MK is a consultant for Reason Why Inc. and has received honoraria from KYORIN Pharmaceutical Co.,Ltd., and has received grants from DAIICHI SANKYO COMPANY, LIMITED, Mitsubishi Tanabe Pharma Corporation, and FUJI YAKUHIN CO., LTD. SH has received honoraria from Mitsubishi Tanabe Pharma Corporation, Bayer Holding Ltd., MSD K.K., and Takeda Pharmaceutical Company Limited. YS is a consultant for Novartis Pharma K.K., ONO PHARMACEUTICAL CO., LTD., and Mitsubishi Tanabe Pharma Corporation, and has received honoraria from Otsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, DAIICHI SANKYO COMPANY, LIMITED, Siemens Healthcare Diagnostics K.K., MSD K.K., Amgen Astellas BioPharma K.K., AstraZeneca K.K., Kowa Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, TEIJIN PHARMA LIMITED, Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Bayer Holding Ltd., Medtronic, Inc., MOCHIDA PHARMACEUTICAL CO., LTD., Novo Nordisk Pharma Ltd., and has received grants from Japan Society for the Promotion of Science, The Ministry of Health, Labour and Welfare Scientific Research, Japan Agency for Medical Research and Development Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, TEIJIN PHARMA LIMITED, Bayer Holding Ltd., DAIICHI SANKYO COMPANY, LIMITED, Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Sanofi K.K., Novartis Pharma K.K., MSD K.K., CHUGAI PHARMACEUTICAL CO., LTD., Kyowa Hakko Kirin Co., Ltd., Nihon Medi-Physics Co.,Ltd., ONO PHARMACEUTICAL CO., LTD., Eli Lilly Japan K.K., FUJI YAKUHIN CO., LTD., Sumitomo Dainippon Pharma Co., Ltd. HS has received consulting fee from Pfizer Japan Inc., and has received honoraria from FUJI YAKUHIN CO., LTD. TN lectured a graduate student who was an employee in FUJI YAKUHIN CO., LTD. for 2 years at Nara medical university, and has two patents regarding to hyperuricemia, and has stock for XORT Therapeutics, and has received grant from FUJI YAKUHIN CO., LTD. Remaining authors have declared that no conflict of interest exists.
: The study was conducted in compliance with the Declaration of Helsinki and according to the Clinical Trials Act (Act No. 16 of April 14, 2017) in Japan. The study protocol was approved by the Nara Medical University Certified Review Board on February 22, 2019 (No. nara0008: CRB5180011). The study shall be started at each site after approval of the protocol by the Ethics Review Committee.
: The investigators will give a sufficient explanation of the study using explanatory documents to each patient and written informed consent will be obtained from all individual participants included in the study before primary enrollment.